MT-2 (Melanotan 2)
Research use only.
High-purity research-grade MT-2 (Melanotan II)
MT-2 (Melanotan II) is a synthetic peptide analog of alpha-melanocyte-stimulating hormone (α-MSH) widely studied for its effects on melanogenesis, pigmentation pathways, and melanocortin receptor activity. It is commonly explored in research involving skin pigmentation, UV-response adaptation, energy balance, and appetite and libido signaling through central melanocortin pathways.
Product overview
MT-2 is a cyclic heptapeptide that acts as an agonist at melanocortin receptors, particularly MC1R, which plays a key role in regulating melanin production in melanocytes. Research involving Melanotan II has primarily focused on its ability to increase eumelanin synthesis, resulting in darker pigmentation responses in experimental models exposed to ultraviolet (UV) radiation. It is also studied for broader melanocortin system effects, which extend to appetite regulation, sexual function pathways, and energy homeostasis.
Key research features
Supports melanogenesis and pigmentation pathways: Studies indicate MT-2 may stimulate melanin production through activation of MC1R receptors, leading to increased pigmentation responses in preclinical models. This mechanism has made it a central compound in pigmentation and photoprotection research.
UV-response and photoprotection research: Research suggests Melanotan II may enhance the skin’s adaptive response to UV exposure by increasing eumelanin levels, which are associated with reduced UV-induced cellular damage in experimental settings.
Melanocortin system activity: MT-2 has been investigated for its broad interaction with melanocortin receptors beyond MC1R, including pathways associated with appetite regulation, energy balance, and central nervous system signaling.
Neurological and endocrine signaling effects: Early research indicates MT-2 may influence sexual arousal pathways and libido-related signaling via central melanocortin receptor activity, making it a compound of interest in neuroendocrine research models.
MT-2 (Melanotan II) Suggested Use:
Typical Dose: 0.25–1 mg per administration
Route: Subcutaneous injection
Frequency: 2–5 times per week (titration-based research protocols)
Duration: 3–8 weeks, or as recommended by a healthcare professional